quetiapine viatris 100 mg filmomh. tabl.
viatris gx bv-srl - quetiapinefumaraat 115,13 mg - eq. quetiapine 100 mg - filmomhulde tablet - quetiapine
quetiapine viatris 200 mg filmomh. tabl.
viatris gx bv-srl - quetiapinefumaraat 230,26 mg - eq. quetiapine 200 mg - filmomhulde tablet - quetiapine
quetiapine viatris 25 mg filmomh. tabl.
viatris gx bv-srl - quetiapinefumaraat 28,78 mg - eq. quetiapine 25 mg - filmomhulde tablet - quetiapine
quetiapine viatris 300 mg filmomh. tabl.
viatris gx bv-srl - quetiapinefumaraat 345,39 mg - eq. quetiapine 300 mg - filmomhulde tablet - quetiapine
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotische middelen - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
apixaban viatris 2.5 mg filmomh. tabl.
viatris gx bv-srl - apixaban 2,5 mg - filmomhulde tablet - 2,5 mg - apixaban 2.5 mg - apixaban
apixaban viatris 2.5 mg filmomh. tabl.
viatris gx bv-srl - apixaban 2,5 mg - filmomhulde tablet - apixaban
apixaban viatris 5 mg filmomh. tabl.
viatris gx bv-srl - apixaban 5 mg - filmomhulde tablet - 5 mg - apixaban 5 mg - apixaban
apixaban viatris 5 mg filmomh. tabl.
viatris gx bv-srl - apixaban 5 mg - filmomhulde tablet - apixaban
irbesartan viatris 75 mg tabl.
viatris gx bv-srl - irbesartan 75 mg - tablet - 75 mg - irbesartan 75 mg - irbesartan